DARK STUDY "DysbetalipoproteinemiA and atheRoma Risk" (DARK)
Recruitment status was: Recruiting
Dysbetalipoproteinemia (type III, Fredrickson's classification) is a rare metabolic disorder. It results from a defect in the clearance of VLDL and chylomicron remnants due to homozygous APOE2 variants or heterozygous APOE mutations, and there is an elevated plasma cholesterol and triglycerides.
As a consequence of the derangements in lipoprotein metabolism, dysbetalipoproteinemia predispose to the premature development of atherosclerosis.
However among this population there is heterogeneity in development of cardiovascular complications and the determinants remain unclear actually.
The aim of the investigators study is to evaluate the intensity of clinical atherosclerosis, and identify its determinants.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Dysbetalipoproteinemia and Atheroma Risk : Assessment of Cardiovascular Risk in Dysbetalipoproteinemic Patients|
- Computed tomographic measurements for coronary-artery calcium [ Time Frame: Day one : the coronary calcium score is assessed on the date of measurement ]Comparison with eventual previous examinations.
- Measurement of carotid intima-media by ultrasonography [ Time Frame: Day one : on the date of measurement ]Comparison with eventual previous examinations.
- Measurement of ankle brachial index [ Time Frame: Day one : on the date of measurement ]Comparison with eventual previous examinations
Biospecimen Retention: Samples With DNA
|Study Start Date:||January 2013|
|Estimated Study Completion Date:||June 2013|
|Estimated Primary Completion Date:||June 2013 (Final data collection date for primary outcome measure)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01760265
|Hospices Civils de Lyon - Groupement Hospitalier Est|
|Bron, France, 69100|
|Principal Investigator:||Philippe MOULIN, Pr||Hospices Civils de Lyon|